EDX-MEDICAL
26.6.2024 10:22:30 CEST | Business Wire | Press release
EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed an exclusive distribution agreement with Curesponse Ltd, to market the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark.
cResponse™ is a groundbreaking platform that biologically assesses how an individual patient’s living tumour tissue responds to selected medicines, identifying the most effective treatment options. It is the only clinical-grade technology providing biological response data for chemotherapy, targeted biologics, and immunotherapy drugs. This platform helps clinicians rapidly pinpoint optimal treatments, potentially saving lives, reducing treatment costs, and accelerating the discovery and development cycles for pharmaceutical companies seeking new cancer drugs.
The cResponse™ platform generates a report ranking selected cancer drugs based on their predicted effect on an individual patient’s tumour, demonstrating over 90% accuracy in clinical trials. The test can be augmented with rapid genomic sequencing to identify additional drug candidates for functional analysis. The entire process is powered by proprietary technologies and advanced AI algorithms. The platform technology has been refined and calibrated using thousands of cancer tissues, demonstrating its clinical utility and effectiveness through hundreds of cases in Israel and the UK. The cResponse™ test is performed at a United Kingdom Accreditation Service (UKAS) accredited lab in London and has also earned a CE mark for Europe, underscoring its regulatory approval and readiness for clinical use.
EDX Medical will initiate commercial activities to support the clinical use of the cResponse™ assay in the UK and Nordics with immediate effect and will explore broadening the agreement with Curesponse in due course.
Professor Sir Chris Evans, OBE, founder of EDX Medical plc, commented: “We are delighted to be increasing accessibility to this genuinely innovative and pioneering test which potentially offers tremendous benefit to those treating cancer and their patients. This product is an excellent addition to our rapidly growing portfolio of class-leading diagnostic solutions.”
Dr Mike Hudson, CEO, EDX Medical plc, said: “We are very pleased to have been selected by Curesponse as their partner, and to be able to make their breakthrough assay available for our clients in the UK and Nordics. We consider cResponse™ to be an outstanding innovation in the fast-moving clinical cancer diagnostic landscape.”
Guy Neev, CEO of Curesponse Ltd, commented: “We are thrilled to partner with EDX Medical Group to bring our cResponse™ platform to patients and clinicians in the UK and Nordic countries. Our mission at Curesponse is to make this technology available to cancer patients to optimize treatment outcomes and save lives. This collaboration is a significant step toward achieving that goal. We look forward to working closely with the EDX Medical team to ensure the successful adoption and implementation of this groundbreaking decision support tool.”
About EDX Medical Group plc
The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX). www.edxmedical.com
About Curesponse Ltd. Curesponse is a pioneering leader in precision oncology. www.curesponse.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626860842/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
TestMu AI Launches Official n8n partner integration, Bringing Real Browser Infrastructure to AI Agent Workflows18.6.2026 15:25:00 CEST | Press release
Developers can now access TestMu AI Browser Cloud directly from n8n workflows, enabling AI agents to operate across 3,000+ browser and operating system environments TestMu AI (formerly LambdaTest), the world's first Full-Stack Agentic AI Quality Engineering platform, today announced the launch of its official TestMu AI Agent partner integration for n8n, one of the fastest-growing workflow automation platforms for AI agents and enterprise automation. Available as an n8n verified and partnered Community Node, the TestMu AI Agent integration enables developers to connect AI agents and automated workflows to TestMu AI's Browser Cloud, providing access to more than 3,000 browser, operating system, and device environments without requiring single line of code as well. As organizations increasingly adopt AI agents for business automation, browser access has emerged as a critical capability. The new integration allows n8n users to equip their workflows with real cloud-hosted browsers capable o
Hytera Wins Two ICCA Awards and Showcases AI-Powered Innovations at CCW 202618.6.2026 15:00:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, concluded a successful participation at Critical Communications World (CCW) 2026 in London, showcasing its latest AI powered and mission critical communications innovations while receiving two awards at the International Critical Communications Awards (ICCAs) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618560904/en/ Hytera is recognized with two ICCA awards at CCW 2026 Held alongside CCW on June 16, the ICCAs ceremony recognized excellence across the global critical communications industry. Hytera received five nominations and won two awards, namely Best Hybrid Device for the Hytera PDC650 Dual-mode Rugged Radio and Best Use of Critical Communications in Transport for Hytera 5G MCX Solution for Xi'an Xianyang International Airport. The recognition highlights Hytera’s continued innovation in critical communications technologie
One NZ Future-Proofs Its Oracle Estate and Accelerates AI Innovation with Rimini Street18.6.2026 15:00:00 CEST | Press release
New Zealand’s leading digital services and connectivity provider partners with Rimini Street to stabilize mission-critical Oracle systems, solve complex interoperability challenges and fund AI transformation Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced One New Zealand (NZ) is leveraging Rimini Street’s support and interoperability solutions to ensure its critical Oracle systems remain secure, stable and reliable, while enabling the organization to redirect investment and talent toward modernization and AI initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618762726/en/ One NZ Future-Proofs Its Oracle Estate and Accelerates AI Innovation with Rimini Street One NZ serves 2 million customers with mobile, broadband and satellite solutions, connecting businesses and communities acro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom